Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.51 |
| ▸ | PDE4A | P27815 | 10/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075710 | 0.86 | POLB (0.53) | PDE4BPDE4DPDE4APDE4CPOLB | |
| SCHEMBL19075725 | 0.79 | MAPT (0.55) | PDE4BPDE4DPDE4APDE4CPOLB | |
| SCHEMBL20697636 | 0.77 | POLB (0.45) | PDE4BPDE4DPDE4APDE4CPOLB | |
| SCHEMBL19083824 | 0.77 | POLB (0.49) | PDE4BPDE4DPDE4APDE4CPOLB | |
| SCHEMBL23914115 | 0.76 | ALDH1A1 (0.43) | — | |
| SCHEMBL19075737 | 0.75 | POLB (0.69) | PDE4BPDE4DPDE4APDE4CPOLB | |
| SCHEMBL7384113 | 0.74 | PDE4B (0.62) | PDE4BPDE4DPDE4APDE4CPOLB | |
| SCHEMBL6799815 | 0.74 | PDE4B (0.71) | PDE4BPDE4DPDE4APDE4CMAPK14 | |
| SCHEMBL19083826 | 0.74 | POLB (0.67) | PDE4BPDE4DPDE4APDE4CPOLB | |
| SCHEMBL6865615 | 0.74 | PDE4D (0.60) | PDE4BPDE4DPDE4APDE4CMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | PDE4B 452/4885PDE4D 461/4885PDE4A 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.